Breast cancer drugs are frequently at the forefront of advances in cancer treatment and diagnosis, especially in CDK4/6 inhibitors, HER2 inhibitors, and HER2-directed mAbs and ADCs [133]. Here, CDK4 is linked to breast carcinoma.